Boston Advisors LLC lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 7.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,182 shares of the life sciences company’s stock after selling 1,514 shares during the period. Boston Advisors LLC’s holdings in Illumina were worth $3,502,000 as of its most recent filing with the SEC.
Other large investors have also recently made changes to their positions in the company. Jennison Associates LLC boosted its stake in shares of Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock valued at $896,589,000 after buying an additional 2,144,576 shares during the last quarter. Vanguard Group Inc. boosted its stake in Illumina by 3.0% in the first quarter. Vanguard Group Inc. now owns 9,648,842 shares of the life sciences company’s stock valued at $1,646,479,000 after buying an additional 285,379 shares in the last quarter. TIAA CREF Investment Management LLC boosted its stake in Illumina by 40.1% in the first quarter. TIAA CREF Investment Management LLC now owns 948,121 shares of the life sciences company’s stock valued at $161,787,000 after buying an additional 271,461 shares in the last quarter. Baird Financial Group Inc. boosted its stake in Illumina by 1,110.5% in the first quarter. Baird Financial Group Inc. now owns 279,120 shares of the life sciences company’s stock valued at $47,629,000 after buying an additional 256,061 shares in the last quarter. Finally, Teachers Advisors LLC boosted its stake in Illumina by 60.7% in the first quarter. Teachers Advisors LLC now owns 384,300 shares of the life sciences company’s stock valued at $65,577,000 after buying an additional 145,231 shares in the last quarter. 93.91% of the stock is owned by institutional investors and hedge funds.
Shares of Illumina, Inc. (NASDAQ:ILMN) traded down 0.98% during trading on Friday, reaching $189.32. 882,072 shares of the company’s stock traded hands. The stock has a market cap of $27.64 billion, a P/E ratio of 37.99 and a beta of 0.83. The company has a 50 day moving average price of $181.43 and a 200-day moving average price of $174.88. Illumina, Inc. has a one year low of $119.37 and a one year high of $199.95.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The business had revenue of $662 million for the quarter, compared to analyst estimates of $642.38 million. During the same quarter in the prior year, the firm posted $0.86 EPS. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, equities research analysts expect that Illumina, Inc. will post $3.65 EPS for the current fiscal year.
Several equities research analysts have recently commented on ILMN shares. Vetr raised shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $196.75 target price for the company in a research report on Monday, April 24th. Cantor Fitzgerald raised their target price on shares of Illumina from $155.00 to $170.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 26th. Cowen and Company reaffirmed an “outperform” rating and issued a $200.00 target price on shares of Illumina in a research report on Wednesday, April 26th. Deutsche Bank AG reaffirmed a “hold” rating and issued a $175.00 target price (up from $165.00) on shares of Illumina in a research report on Saturday, April 29th. Finally, Morgan Stanley reaffirmed an “underweight” rating and issued a $115.00 target price (up from $108.00) on shares of Illumina in a research report on Monday, May 15th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $177.01.
In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 6th. The stock was sold at an average price of $180.24, for a total value of $3,604,800.00. Following the sale, the director now owns 539,176 shares in the company, valued at approximately $97,181,082.24. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Jay T. Flatley sold 15,000 shares of the stock in a transaction that occurred on Tuesday, July 18th. The shares were sold at an average price of $170.77, for a total value of $2,561,550.00. Following the transaction, the director now owns 534,176 shares in the company, valued at approximately $91,221,235.52. The disclosure for this sale can be found here. In the last 90 days, insiders sold 154,010 shares of company stock worth $27,840,615. Insiders own 1.60% of the company’s stock.
About Illumina
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
